SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
Mizuho Securities analyst Uy Ear maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of $9.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Evolus, and Sarepta Therapeutics. According to TipRanks, Ear has an average return of -3.5% and a 34.48% success rate on recommended stocks.
Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $8.42.
SAGE market cap is currently $486.6M and has a P/E ratio of -1.18.
Read More on SAGE:
Disclaimer & DisclosureReport an Issue
- Sage Therapeutics reports Q1 EPS ($1.01), consensus ($1.01)
- Is SAGE a Buy, Before Earnings?
- Cautious Outlook on SAGE Therapeutics: Hold Rating Maintained Amid EPS Adjustments and Revenue Forecast Revisions
- Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
- Sage Therapeutics resumed with an Underperform at BofA
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.